| Year |
Citation |
Score |
| 2014 |
Friedman LS, Simmons LH, Goldman RH, Sohani AR. Case records of the Massachusetts General Hospital. Case 12-2014. A 59-year-old man with fatigue, abdominal pain, anemia, and abnormal liver function. The New England Journal of Medicine. 370: 1542-50. PMID 24738672 DOI: 10.1056/NEJMcpc1314242 |
0.338 |
|
| 2012 |
Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6771-83. PMID 23136191 DOI: 10.1158/1078-0432.Ccr-12-2347 |
0.407 |
|
| 2012 |
Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T, Tremayne J, Ross LB, Pei Z, Friedman LS, Blackwood EM, Belvin M. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Letters. 326: 168-75. PMID 22902509 DOI: 10.1016/j.canlet.2012.08.011 |
0.404 |
|
| 2011 |
Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, ... ... Friedman LS, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Molecular Cancer Therapeutics. 10: 2426-36. PMID 21998291 DOI: 10.1158/1535-7163.MCT-11-0446 |
0.414 |
|
| 1972 |
Latané B, Friedman L, Thomas J. Affiliation in rats under stress Psychonomic Science. 27: 39-40. DOI: 10.3758/Bf03328883 |
0.472 |
|
| Show low-probability matches. |